These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31578258)

  • 1. The Novel Phosphodiesterase 9A Inhibitor BI 409306 Increases Cyclic Guanosine Monophosphate Levels in the Brain, Promotes Synaptic Plasticity, and Enhances Memory Function in Rodents.
    Rosenbrock H; Giovannini R; Schänzle G; Koros E; Runge F; Fuchs H; Marti A; Reymann KG; Schröder UH; Fedele E; Dorner-Ciossek C
    J Pharmacol Exp Ther; 2019 Dec; 371(3):633-641. PubMed ID: 31578258
    [No Abstract]   [Full Text] [Related]  

  • 2. PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition.
    Kroker KS; Mathis C; Marti A; Cassel JC; Rosenbrock H; Dorner-Ciossek C
    Neurobiol Aging; 2014 Sep; 35(9):2072-8. PubMed ID: 24746365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.
    Kleiman RJ; Chapin DS; Christoffersen C; Freeman J; Fonseca KR; Geoghegan KF; Grimwood S; Guanowsky V; Hajós M; Harms JF; Helal CJ; Hoffmann WE; Kocan GP; Majchrzak MJ; McGinnis D; McLean S; Menniti FS; Nelson F; Roof R; Schmidt AW; Seymour PA; Stephenson DT; Tingley FD; Vanase-Frawley M; Verhoest PR; Schmidt CJ
    J Pharmacol Exp Ther; 2012 May; 341(2):396-409. PubMed ID: 22328573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents.
    Hutson PH; Finger EN; Magliaro BC; Smith SM; Converso A; Sanderson PE; Mullins D; Hyde LA; Eschle BK; Turnbull Z; Sloan H; Guzzi M; Zhang X; Wang A; Rindgen D; Mazzola R; Vivian JA; Eddins D; Uslaner JM; Bednar R; Gambone C; Le-Mair W; Marino MJ; Sachs N; Xu G; Parmentier-Batteur S
    Neuropharmacology; 2011 Sep; 61(4):665-76. PubMed ID: 21619887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP.
    Kroker KS; Rast G; Giovannini R; Marti A; Dorner-Ciossek C; Rosenbrock H
    Neuropharmacology; 2012 Apr; 62(5-6):1964-74. PubMed ID: 22245562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance.
    Boess FG; Hendrix M; van der Staay FJ; Erb C; Schreiber R; van Staveren W; de Vente J; Prickaerts J; Blokland A; Koenig G
    Neuropharmacology; 2004 Dec; 47(7):1081-92. PubMed ID: 15555642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents.
    van der Staay FJ; Rutten K; Bärfacker L; Devry J; Erb C; Heckroth H; Karthaus D; Tersteegen A; van Kampen M; Blokland A; Prickaerts J; Reymann KG; Schröder UH; Hendrix M
    Neuropharmacology; 2008 Oct; 55(5):908-18. PubMed ID: 18674549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Object memory enhancement by combining sub-efficacious doses of specific phosphodiesterase inhibitors.
    Bollen E; Akkerman S; Puzzo D; Gulisano W; Palmeri A; D'Hooge R; Balschun D; Steinbusch HW; Blokland A; Prickaerts J
    Neuropharmacology; 2015 Aug; 95():361-6. PubMed ID: 25896769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.
    Verhoest PR; Fonseca KR; Hou X; Proulx-Lafrance C; Corman M; Helal CJ; Claffey MM; Tuttle JB; Coffman KJ; Liu S; Nelson F; Kleiman RJ; Menniti FS; Schmidt CJ; Vanase-Frawley M; Liras S
    J Med Chem; 2012 Nov; 55(21):9045-54. PubMed ID: 22780914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel role for cyclic guanosine 3',5'monophosphate signaling in synaptic plasticity: a selective suppressor of protein kinase A-dependent forms of long-term potentiation.
    Makhinson M; Opazo P; Carlisle HJ; Godsil B; Grant SG; O'Dell TJ
    Neuroscience; 2006 Jun; 140(2):415-31. PubMed ID: 16549271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of phosphodiesterase 9A as a cyclic guanosine monophosphate-specific phosphodiesterase in germinal vesicle oocytes: a proposed role in the resumption of meiosis.
    Hanna CB; Yao S; Wu X; Jensen JT
    Fertil Steril; 2012 Aug; 98(2):487-95.e1. PubMed ID: 22704629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The type IV-specific phosphodiesterase inhibitor rolipram and its effect on hippocampal long-term potentiation and synaptic tagging.
    Navakkode S; Sajikumar S; Frey JU
    J Neurosci; 2004 Sep; 24(35):7740-4. PubMed ID: 15342741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats.
    Rutten K; Van Donkelaar EL; Ferrington L; Blokland A; Bollen E; Steinbusch HW; Kelly PA; Prickaerts JH
    Neuropsychopharmacology; 2009 Jul; 34(8):1914-25. PubMed ID: 19262466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDE4 inhibition enhances hippocampal synaptic plasticity in vivo and rescues MK801-induced impairment of long-term potentiation and object recognition memory in an animal model of psychosis.
    Wiescholleck V; Manahan-Vaughan D
    Transl Psychiatry; 2012 Mar; 2(3):e89. PubMed ID: 22832854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of PDE2A, but not PDE9A, modulates presynaptic short-term plasticity measured by paired-pulse facilitation in the CA1 region of the hippocampus.
    Fernández-Fernández D; Rosenbrock H; Kroker KS
    Synapse; 2015 Oct; 69(10):484-96. PubMed ID: 26178667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling.
    Wang PX; Li ZM; Cai SD; Li JY; He P; Huang Y; Feng GS; Luo HB; Chen SR; Liu PQ
    Acta Pharmacol Sin; 2017 Sep; 38(9):1257-1268. PubMed ID: 28649129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid-β Peptide Is Needed for cGMP-Induced Long-Term Potentiation and Memory.
    Palmeri A; Ricciarelli R; Gulisano W; Rivera D; Rebosio C; Calcagno E; Tropea MR; Conti S; Das U; Roy S; Pronzato MA; Arancio O; Fedele E; Puzzo D
    J Neurosci; 2017 Jul; 37(29):6926-6937. PubMed ID: 28626017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus.
    Suvarna NU; O'Donnell JM
    J Pharmacol Exp Ther; 2002 Jul; 302(1):249-56. PubMed ID: 12065724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase 9a Inhibition in Mouse Models of Diastolic Dysfunction.
    Methawasin M; Strom J; Borkowski T; Hourani Z; Runyan R; Smith JE; Granzier H
    Circ Heart Fail; 2020 May; 13(5):e006609. PubMed ID: 32418479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of phosphodiesterase (1B, 2A, 9A and 10A) inhibitors on central nervous system cyclic nucleotide levels in rats and mice.
    Chen J; Zook D; Crickard L; Tabatabaei A
    Neurochem Int; 2019 Oct; 129():104471. PubMed ID: 31121256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.